HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

AuthorsM O'Keefe
JournalIrish medical journal (Ir Med J) 2011 Jul-Aug Vol. 104 Issue 7 Pg. 197 ISSN: 0332-3102 [Print] Ireland
PMID21957683 (Publication Type: Editorial)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Retinopathy of Prematurity (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: